DOCSHealthcare · Health Information ServicesThe 21 Wall Street analysts covering Doximity, Inc. hold a median 12-month price target of $28 — -8.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 12 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Doximity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (94): The business earns solid, repeatable profits on what it owns.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DOCS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −8.3% from it.
Of the 20 most recent actions, 6 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Evercore ISI Group | Maintains | In-Line | $40 → $35 |
| 8 Sept 2026 | Freedom Capital Markets | Downgrade | Hold | — |
| 8 Sept 2026 | Freedom Capital Markets | Downgrade | Hold | $24 → $27 |
| 21 Aug 2026 | Barclays | Maintains | Equal-Weight | $20 → $27 |
| 21 Aug 2026 | Barclays | Maintains | Equal-Weight | — |
| 13 Aug 2026 | Truist Securities | Maintains | Hold | — |
| 13 Aug 2026 | Truist Securities | Maintains | Hold | $19 → $24 |
| 10 Aug 2026 | Wells Fargo | Downgrade | Underweight | — |
| 10 Aug 2026 | Wells Fargo | Downgrade | Underweight | $18 |
| 7 Aug 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 7 Aug 2026 | Evercore ISI Group | Maintains | In-Line | $22 → $40 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | — |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $26 → $31 |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 7 Aug 2026 | Piper Sandler | Reiterates | Overweight | $42 → $47 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $38 → $20 |
| 15 May 2026 | Barclays | Downgrade | Equal-Weight | — |
| 15 May 2026 | Goldman Sachs | Maintains | Neutral | — |
| 14 May 2026 | Baird | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DOCS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Doximity, Inc. returned −54.7% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 16% of US stocks
Cheaper than 16% of US stocks
Cheaper than 15% of US stocks
Higher than 45% of US stocks
Higher than 10% of US stocks
Higher than 94% of US stocks
Higher than 81% of US stocks
Higher than 86% of US stocks
Higher than 78% of US stocks
Higher than 93% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Doximity, Inc. has a market value of $5.4B and an enterprise value of $4.8B.
Revenue in the twelve months to 30 June 2026: $655.6M. The latest quarter grew 7.3% year on year.
Net income over the same four quarters: $167.0M, a 25.5% net margin.
Diluted earnings per share, trailing twelve months: $0.85.
Free cash flow in the twelve months to 30 June 2026: $297.0M.
Doximity, Inc. spent $400.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 35.9×; forward P/E: 19.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Doximity, Inc. employs 880 people — $745K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Doximity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The DJS Law Group announced a class action lawsuit against Doximity alleging violations of federal securities laws. It encouraged shareholders who purchased DOCS shares during the stated class period to contact the firm about possible lead plaintiff appointments.
Why it matters — The lawsuit is a legal development involving Doximity and its shareholders.
Schall, Brown & Schwartz LLP said it is reminding investors of a class action lawsuit against Doximity alleging violations of federal securities laws. The firm encouraged shareholders who purchased DOCS shares during the stated class period to contact it about possible lead plaintiff appointments.
Why it matters — The lawsuit and potential lead plaintiff appointments are relevant developments for investors following Doximity.
Bernstein Liebhard LLP reminded Doximity investors of a November 16, 2026 deadline related to a securities fraud class action lawsuit against the company.
Why it matters — The notice concerns an ongoing securities fraud class action and a deadline relevant to Doximity shareholders.
Doximity extended its 13-year partnership with U.S. News & World Report. Doximity powers U.S. News' Doctor Finder and Patient Connect appointment-booking tools, which are used by more than 65 million Americans annually to find and schedule care.
Why it matters — The extension reinforces Doximity's role as a data provider for U.S. News' physician- and hospital-facing products.
Rosen Law Firm reminded purchasers of Doximity common stock from August 8, 2024, through May 13, 2026, of a November 16, 2026 deadline to seek lead plaintiff status in a securities fraud lawsuit. Eligible purchasers may be entitled to compensation through a contingency fee arrangement without out-of-pocket fees or costs.
Why it matters — The notice concerns potential litigation and compensation claims involving DOCS shareholders who purchased during the stated period.
The 21 Wall Street analysts covering Doximity, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $47. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 21 analysts covering Doximity, Inc., 8 rate it a Buy, 11 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Doximity, Inc. 60 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Doximity, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (94 of 100).
No one can know that. What the data says: the median 12-month target from 21 analysts implies -8.3% from the last close, and Ticker Nerd's factor model ranks Doximity, Inc. 60 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Doximity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DOCS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $47 over the next 12 months.
Doximity, Inc. returned -54.7% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals.
The most recent item we track (PRNewsWire, 14 Oct 2026): "Doximity, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOCS". The DJS Law Group announced a class action lawsuit against Doximity alleging violations of federal securities laws. It encouraged shareholders who purchased DOCS shares during the stated class period to contact the firm about possible lead plaintiff appointments.
Doximity Inc. Class A Common Stock represents ownership in Doximity, a U.S.-based digital platform built for medical professionals. Doximity provides cloud-based tools that help physicians, nurse practitioners, physician assistants, and medical students collaborate with colleagues, coordinate patient care, conduct virtual patient visits, access curated medical news and research, and manage careers and on-call schedules. The company focuses on healthcare communications and workflow software, serving the medical community through features designed for secure networking, telehealth support, and professional productivity. Doximity plays a notable role in the health information services market by connecting clinicians with tools that support day-to-day clinical coordination and access to specialty-specific information.
CEO Mr. Jeffrey A. Tangney · 880 employees · United States · https://www.doximity.com
